Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
IO monotherapy
PD-L1 expression
cemiplimab
cemiplimab monotherapy
network meta-analysis
non-small-cell lung cancer
systematic literature review
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
11
2021
accepted:
16
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) Relevant RCTs were identified by searching databases and conference proceedings as per ISPOR, NICE, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. NMA with time-varying hazard ratios (HRs) was performed for OS and PFS. Analyses were conducted for objective response rate (ORR) and safety/tolerability. Fixed-effect models were used due to limited evidence. Various sensitivity analyses were conducted to validate the base case analyses. The feasibility assessment determined that EMPOWER-Lung 1, KEYNOTE-024, and KEYNOTE-042 trials were eligible. IMpower110 was excluded because an incompatible PD-L1 assay (SP142) was used for patient selection. For first-line advanced NSCLC with PD-L1 ⩾50%, cemiplimab was associated with statistically significant improvements in PFS [HR (95% credible interval [CrI]): 0.65 (0.50-0.86), 1-12 months] and ORR [odds ratio (OR) (95% CrI): 1.64 (1.04-2.62)], and comparable OS [HR (95% CrI): 0.77 (0.54-1.10), 1-12 months] Considering the limitations of indirect treatment comparisons, in patients with advanced NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated significant improvements in PFS and ORR, comparable OS, and no evidence of differences in safety/tolerability
Sections du résumé
Background
UNASSIGNED
For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS)
Methods
UNASSIGNED
Relevant RCTs were identified by searching databases and conference proceedings as per ISPOR, NICE, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. NMA with time-varying hazard ratios (HRs) was performed for OS and PFS. Analyses were conducted for objective response rate (ORR) and safety/tolerability. Fixed-effect models were used due to limited evidence. Various sensitivity analyses were conducted to validate the base case analyses.
Results
UNASSIGNED
The feasibility assessment determined that EMPOWER-Lung 1, KEYNOTE-024, and KEYNOTE-042 trials were eligible. IMpower110 was excluded because an incompatible PD-L1 assay (SP142) was used for patient selection. For first-line advanced NSCLC with PD-L1 ⩾50%, cemiplimab was associated with statistically significant improvements in PFS [HR (95% credible interval [CrI]): 0.65 (0.50-0.86), 1-12 months] and ORR [odds ratio (OR) (95% CrI): 1.64 (1.04-2.62)], and comparable OS [HR (95% CrI): 0.77 (0.54-1.10), 1-12 months]
Conclusions
UNASSIGNED
Considering the limitations of indirect treatment comparisons, in patients with advanced NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated significant improvements in PFS and ORR, comparable OS, and no evidence of differences in safety/tolerability
Identifiants
pubmed: 35747163
doi: 10.1177/17588359221105024
pii: 10.1177_17588359221105024
pmc: PMC9210099
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221105024Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: Nick Freemantle declares consulting services for ALK, Allergan, Aimmune, AstraZeneca, Gilead, Grifols, Ipsen, MSD, Novartis, Novo Nordisk, Sanofi Aventis, and Vertex; and speaking services for Abbott Singapore and Sanofi Aventis. Yingxin Xu, Chieh-I Chen, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, and Petra Rietschel are employees and stockholders of Regeneron Pharmaceuticals, Inc. Florence R. Wilson, Sam Keeping, Keith Chan, and Emily Glowienka are employees of Precision HEOR and received funding to produce this work. Patricia Guyot, Gerasimos Konidaris, and Kokuvi Atsou are employees of Sanofi and may own shares or stock options in the company.
Références
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
BMC Med. 2014 Jun 05;12:93
pubmed: 24898705
J Thorac Oncol. 2022 Feb;17(2):289-308
pubmed: 34648948
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
Cancer Sci. 2020 Dec;111(12):4480-4489
pubmed: 32926507
BMC Med. 2013 Jul 04;11:159
pubmed: 23826681
Lung Cancer. 2019 Aug;134:174-179
pubmed: 31319978
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Stat Med. 2015 Mar 15;34(6):984-98
pubmed: 25475839
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
ESMO Open. 2021 Jun;6(3):100164
pubmed: 34091263
J Natl Compr Canc Netw. 2019 May 1;17(5.5):574-578
pubmed: 31117034
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Clin Cancer Res. 2019 Nov 1;25(21):6339-6345
pubmed: 31345838
Value Health. 2011 Jun;14(4):429-37
pubmed: 21669367
Sci Rep. 2015 Aug 17;5:13110
pubmed: 26279307
Value Health. 2011 Jun;14(4):417-28
pubmed: 21669366
Int J Cancer. 2021 May 1;148(9):2313-2320
pubmed: 33231285
J Clin Oncol. 2021 Jul 20;39(21):2327-2338
pubmed: 33513313
Transl Lung Cancer Res. 2021 Jul;10(7):3106-3119
pubmed: 34430351
J Clin Med. 2021 Mar 26;10(7):
pubmed: 33810441
Ann Transl Med. 2019 Jul;7(Suppl 3):S127
pubmed: 31576334
Front Oncol. 2021 Sep 13;11:698199
pubmed: 34589422
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Clin Lung Cancer. 2020 Nov;21(6):e511-e515
pubmed: 32389509
Ann Transl Med. 2019 Jul;7(Suppl 3):S140
pubmed: 31576347
Ann Oncol. 2019 Nov 1;30(11):1686-1688
pubmed: 31504132
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Med Decis Making. 2013 Jul;33(5):607-17
pubmed: 23104435
PLoS One. 2018 Nov 8;13(11):e0206370
pubmed: 30408065
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100
pubmed: 29346180
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Front Immunol. 2021 Aug 16;12:731546
pubmed: 34484242
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
Ther Drug Monit. 2018 Feb;40(1):9-16
pubmed: 29084031
Lancet Oncol. 2022 Feb;23(2):220-233
pubmed: 35038432
Immunology. 2015 Jun;145(2):182-201
pubmed: 25826229
Adv Ther. 2019 Oct;36(10):2600-2617
pubmed: 31432460
JAMA Oncol. 2020 May 1;6(5):661-674
pubmed: 32271377
J Thorac Dis. 2018 Jul;10(Suppl 18):S2127-S2129
pubmed: 30123540
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Pharmacol Ther. 2019 Feb;194:84-106
pubmed: 30268773
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977